CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01083758
NCT01083758Phase 2Completed
CompareCT.gov

Effect of Calcipotriol Plus Betamethasone Dipropionate Topical Suspension on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 17 Years) With Scalp Psoriasis

LEO Pharma·interventional·Posted Mar 10, 2010·Updated Mar 11, 2025

In Brief

A Phase 2 clinical trial evaluating LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) for Scalp Psoriasis. Completed, enrolled 31 participants across 6 sites.

Detailed Summary

The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 topical suspension in adolescent subjects (aged 12 to 17 years) with scalp psoriasis. LEO 80185 topical suspension has marketing approval in many countries under the brand names Taclonex Scalp® Topical Suspension and Xamiol® gel for the treatment of scalp psoriasis in adults. No studies have been performed in subjects younger than 18 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScalp Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2010
Enrollment StartApr 1, 2010
Primary CompletionAug 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.3 years ago

Interventions

LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)drug

Topical suspension applied once daily for up to 8 weeks